In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2 New antiretroviral drugs are needed to treat HIV-2 infected patients failing therapy. Herein, we evaluate the activity of novel reverse transcriptase inhibitors tenofovir alafenamide (TAF) and OBP-601(2,3-didehydro-3-deoxy-4-ethynylthymidine) against primary isolates from HIV-2 infected patients experiencing virologic failure. TAF and OBP-601 were tested against twelve primary isolates obtained from nine drug-experienced patients failing therapy and three drug naïve patients using a single-round infectivity assay in TZM-bl cells. The RTcoding region of pol was sequenced and the GRADE algorithm was used to identify resistance profiles and mutations. TAF and OBP-601 inhibited the replication of almost all isolates at a median EC 50 of 0.27 nM and 6.83 nM, respectively. Two isolates showed moderate-level resistance to OBP-601 or TAF and two other isolates showed high-level resistance to OBP-601 or to both drugs. With one exception, all resistant viruses had canonical nucleoside reverse transcriptase inhibitors (NRTIs)-associated resistance mutations (K65R, N69S, V111I, Y115F, Q151M and M184V). Our results show that TAF has potent activity against most multi-drug resistant HIV-2 isolates and should be considered for the treatment of HIV-2 infected patients failing therapy.
There are about 1-2 million people infected with HIV-2 worldwide most living in West Africa , Portugal (Carvalho et al., 2012) , France (Cazein et al., 2015) and India (Gurjar et al., 2009) . HIV-2 is less pathogenic than HIV-1 and progression to AIDS in the absence of antiretroviral treatment (ART) is much slower in HIV-2-infected patients (on average ≥ 20 years for HIV-2 vs 10 years for HIV-1 infection) (Damond et al., 2011; Gottlieb et al., 2002) . As for HIV-1, ART prevents disease progression to AIDS and death (de Silva et al., 2008; Hansmann et al., 2005) . However, options available for the treatment of HIV-2 infected patients are still limited since, in contrast to HIV-1, HIV-2 is naturally resistant to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and fusion inhibitors, and it presents a reduced sensitivity to some protease inhibitors (PIs) [reviewed in (Menendez-Arias and Alvarez, 2014) ]. Moreover, most ART regimens used in HIV-1 infected patients are unable to suppress viral replication in HIV-2 infected patients or to significantly increase the number of CD4 + T lymphocytes (Soares et al., 2011) . Finally, HIV-2 has a lower genetic barrier to resistance to current drugs compared to HIV-1 (Ntemgwa et al., 2007 (Ntemgwa et al., , 2009 Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir. Compared with TDF, TAF is more stable in blood and plasma (Lee et al., 2005) , has more favorable renal and bone safety profiles (Sax et al., 2014 (Sax et al., , 2015 and has higher anti-HIV-1 activity at ten times lower oral doses in humans as measured by the reduction in viral load (Ruane et al., 2013) .
HIV exploits two distinct resistance mechanisms against NRTIs (reviewed in Iyidogan and Anderson, 2014) . First, selection of resistance mutations such as K65R in RT leads to an increase in discrimination against NRTIs by reducing the enzyme's binding affinity to the nucleoside analogue triphosphate derivatives or decreasing the incorporation rates of these nucleotides. In the excision repair mechanism, acquisition of thymidine analogue resistance mutations (TAMs) (i.e. M41L, D67N, K70R, L210W, T215F/Y and K219E/Q) leads to the phosphorolytic removal of the chain-terminating NRTI from the primer terminus subsequent to its incorporation into viral DNA. The excision repair mechanism is rarely used by HIV-2 to acquire resistance to NRTIs (Ntemgwa et al., 2009) , which is related to the presence of a methionine at position 73 in RT, instead of lysine as found in HIV-1 (Alvarez et al., 2018) .
In vitro studies have shown that HIV-1 has a higher genetic barrier to resistance to TAF than to TDF (Margot et al., 2016b) . Nonetheless, like in TDF-based regimens, resistance to TAF-based regimens in HIV-1 infected patients is associated with the K65R substitution in RT (with or without S68G and A62V) and preexisting TAMs (M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E/N/R) (Margot et al., 2006 (Margot et al., , 2016a (Margot et al., , 2017 McColl et al., 2004; Miller et al., 2004) .
Very limited information exists regarding the activity of TDF and TAF on HIV-2. One study found that TDF inhibited the replication of HIV-2 strains ROD and EHO at similar EC 50 values relative to HIV-1 strain IIIB (EC 50 = 1.12 μg/ml and 1.05 μg/ml vs 1.15 μg/ml) (Witvrouw et al., 2004) . Similar results were found in another study comparing the sensitivity of HIV-2 ROD and HIV-1 NL4-3 to TDF (EC 50 = 7.2 μM vs 7.2 μM) (Smith et al., 2008) . One recent in vitro study performed on a few primary isolates (n = 3) has shown that TAF inhibits HIV-2 replication with a mean EC 50 of 1.83 nM (compared with 3.63 nM for HIV-1) . In HIV-2 infected patients resistance to TDF occurs via selection of the K65R and Q151M mutations . V111I may be coselected with Q151M in some HIV-2 patients and increases the replication capacity of viruses with K65R and Q151M (Charpentier et al., 2013; Damond et al., 2005; Descamps et al., 2004; Deuzing et al., 2015) .
OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) is a novel thymidine analogue that inhibits reverse transcriptase activity. Relative to stavudine, OBP-601 is more potent against HIV-1 and causes less cellular and mitochondrial toxicity in cell culture (Dutschman et al., 2004) . It is also active against most NRTI-resistant HIV-1 mutants (Li et al., 2013; Nitanda et al., 2005) . In a phase IIb clinical trial the combination of lamivudine (3TC), efavirenz (EFV), and OBP601 (400 mg once a day) resulted in virologic suppression in 94% of HIV-1-infected subjects after 24 weeks of treatment, compared with 89% in the combination TDF (300 mg once a day)+3TC + EFV. However, this trial was terminated due to higher rates of resistance (11% OBP-601 vs 1% for TDF) and gains in both peripheral and central fat for patients taking OBP-601 (Gupta et al., 2016) . Interestingly, a recent study performed mainly with lab-adapted HIV-2 isolates (6 of 8) from ARV-naïve patients found that OBP-601 was 9.5-fold more potent against HIV-2 than against HIV-1 in vitro (mean EC 50 for HIV-1 was 610.00 nM vs 64.12 nM for HIV-2) suggesting that OBP-601 at lower doses may be useful to treat HIV-2 infected patients (Smith et al., 2015) . Using site directed mutagenesis the authors also found that K65R mutation conferred HIV-2 ROD 3.2-fold hypersusceptibility to OBP-601 whereas Q151M alone had no effect in susceptibility. On the other hand, M184V and K65R + M184V HIV-2 ROD mutants were 15-and 16-fold more resistant to OBP-601, respectively; even higher levels of resistance were observed for Q151M + M184V, K65R + Q151M + M184V and K65R + N69S + V111I + Q151M + M184V mutants (53-, 111-and 105-fold, respectively).
In this study we performed the first comparative evaluation of the activity of TDF, TAF and OBP-601 against primary isolates of HIV-2 obtained from drug naïve patients and patients failing ART.
TAF and TDF were provided by Gilead Sciences. OBP-601 was provided by Oncolys BioPharma. All but three of the twelve HIV-2 group A isolates used in this study were described before (Borrego et al., 2012; Doring et al., 2016) . Three were obtained from drug naïve patients and nine were from drug-experienced patients (Table S1 ). The three new isolates, named 10PTHSJIG, 15PTHSJIG and 15PTHCEC, were obtained recently from two patients failing therapy. HIV-1 reference strain NL4-3 was obtained by transfection of HEK293T cells with pNL4-3 plasmid using Fugene 6 reagent (Roche, Switzerland) according to manufacturer's instructions.
The antiviral activity of TAF, OBP-601 and TDF was evaluated using Drug resistance mutations in the RT-coding region of the pol gene were determined by sequencing analysis. Briefly, RNA was extracted from the isolates presenting phenotypic drug resistance using Nuclisens Isolation Kit (Organon Teknika, Holland) and nested PCR was done to obtain a 1305 bp fragment corresponding to protease and the first half of the reverse transcriptase using outer primers JA218 and JA221 and inner primers JA219 and JA220 (Table S2 ). Thermal cycling conditions for amplification and sequencing of this region, primer numbers and positions have been described previously (Brandin et al., 2003) . DNA sequences were obtained with Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, USA) according to the manufacturers recommendations and the sequences were run on an automated DNA sequencer model 310 ABI Genetic Analyser (Applied Biosystems, USA). The GRADE algorithm was used to identify resistance mutations (http://www.hiv-grade.de/) and estimate virus susceptibility to the different antiretroviral drugs.
Evolutionary relationships and genotype of the viruses was determined by phylogenetic analysis of the RT sequences using the PhyML program implemented in SeaView software using the nearest-neighbor interchange heuristic search strategy and 1000 bootstrap replications.
In phylogenetic analysis all isolates clustered within group A which is the most common HIV-2 group in Portugal and worldwide (Visseaux et al., 2016) (Fig. S1 ). In addition, isolates 10PTHJSIG and 15PTHJSIG formed a monophyletic cluster confirming their common origin.
Maximum percentage of inhibition (MPI) of the HIV-2 isolates was similar for TAF, TDF and OBP-601 (TDF, 93.8%; TAF, 94.1%; OBP-601, 96.2%, P > 0.05). Median EC 50 of TAF against HIV-2 isolates was 0.27 nM (range 0.04-12.95 nM) which was 3.2-fold lower compared to TDF ( Fig. 1 and Table 1 ). In contrast, median EC 50 of OBP-601 was significantly higher (6.83 nM, range 0.65-2781 nM) than TDF and TAF ( Fig. 1 and Table 1 ). Similar results were obtained for the EC 90 indicating that OBP-601 is significantly less potent against HIV-2 than TAF and TDF [Median (range), TDF 13.49 nM (3.95-71.43); TAF, 5.96 nM (1.00-164.40); OBP-601, 188.20 (10.31-28843 .00), P < 0.001]. Regarding TDF and OBP-601, our results are in line with those obtained by Smith and collaborators (Smith et al., 2015) with the lab-adapted isolate HIV-2 ROD9. Two isolates showed moderate-level resistance (MLR) to OBP-601 (10PTHSJIG) or to TAF and TDF (15PTHCEC). Two other isolates showed high-level resistance (HLR) to OBP-601 (00PTHCC20) or to TAF and OBP-601 (03PTHSM9). Despite the HLR to TAF and OBP-601, no known NRTI resistance mutations were found in the RT of isolate 03PTHSM9, only some polymorphisms that so far have not been related with resistance (K4R, I5V, R22K, T58S, K64R, D86E, L109I, Y162H, I167V P176Q, G211N, Q228R, I244V). In contrast, Q151M and K223R substitutions were found in isolate 00PTHCC20 and V111I, Y115F, Q151M and M184V in 10PTHSJIG (Table 1 ). The latter was the only resistance mutation that remained in the isolate obtained from this patients five years later (15PTHSJIG) ( Table 1) . Finally, substitutions K65R and N69S were found in isolate 15PTHCEC.
In this study, we performed the first side-by-side characterization of the activity of the novel NRTIs TAF and OBP-601 against twelve primary isolates of HIV-2, nine of which were obtained from ART-experienced patients. So far only one study had examined the activity of TAF against primary isolates (n = 3) of HIV-2 ; our results with 4-times more isolates and a different inhibition method were similar to this study (EC 50 of 1.6 nM vs 1.8 nM) confirming that TAF is a potent inhibitor of HIV-2.
Two isolates obtained from two drug-experienced patients were resistant to TAF. Isolate 03PTHSM9 was highly resistance to TAF and to OBP-601 despite being sensitive to TDF. This occurred in the absence of canonical NRTI resistance mutations revealing that there are TAF and OBP-601-specific HIV-2 resistance mutations yet to be identified. showing that the isolate obtained at this time was moderately resistant to TDF and TAF, and the presence of mutations K65R and N69S in the RT, are highly consistent with the history of failing therapy with multiple NRTIs including TDF. OBP-601 had a potent activity against nine of the twelve (75%) isolates that were tested confirming its potential usefulness against HIV-2 ( Smith et al., 2015) . Two isolates from drug-experienced patients, 00PTHCC20 and 03PTHSM9, showed HLR to OBP-601. Isolate 03PTHSM9 had no known NRTI resistance mutations and was discussed above. Isolate 00PTHCC20 had the Q151M and K223R mutations that have been previously associated to HLR to AZT, d4T, ddI and ABC, and LLR to 3TC, FTC and TDF (Charpentier et al., 2013) . Isolate 10PTHSJIG showed MLR to OBP-601 consistent with the resistance mutations with DRV/r + MVC150 + DTG. Hence, the long period of absence of NRTI pressure in this patient has allowed the return of the wild-type strain in 2015 which was sensitive to TAF, TDF and OPB-601 (Deeks et al., 2001; Paquet et al., 2011) .
In conclusion, TAF has a potent activity against most multi-drug resistant HIV-2 isolates and should be considered for the treatment of HIV-2 infected individuals failing therapy. Identification of one isolate with resistance to TAF and OBP-601 without canonical resistance mutations is of concern and warrants further investigation to identify the determinants of resistance. 
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